[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 79, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 905293, "exercisedValue": 0, "unexercisedValue": 219686}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rosa  Ferrao", "title": "Senior VP of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9281, "open": 0.9302, "dayLow": 0.86, "dayHigh": 0.9783, "regularMarketPreviousClose": 0.9281, "regularMarketOpen": 0.9302, "regularMarketDayLow": 0.86, "regularMarketDayHigh": 0.9783, "payoutRatio": 0.0, "beta": 0.749, "forwardPE": -0.4504651, "volume": 772578, "regularMarketVolume": 764377, "averageVolume": 1192961, "averageVolume10days": 1613140, "averageDailyVolume10Day": 1613140, "bid": 0.9278, "ask": 0.9951, "bidSize": 1, "askSize": 1, "marketCap": 68889496, "fiftyTwoWeekLow": 0.783, "fiftyTwoWeekHigh": 5.66, "fiftyDayAverage": 1.42436, "twoHundredDayAverage": 2.054715, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -139679968, "profitMargins": 0.0, "floatShares": 50908491, "sharesOutstanding": 71130096, "sharesShort": 6909590, "sharesShortPriorMonth": 6623831, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0971, "heldPercentInsiders": 0.04464, "heldPercentInstitutions": 0.82629997, "shortRatio": 8.76, "shortPercentOfFloat": 0.11359999, "impliedSharesOutstanding": 71130096, "bookValue": 3.572, "priceToBook": 0.2711366, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -135122000, "trailingEps": -1.97, "forwardEps": -2.15, "enterpriseToEbitda": 0.943, "52WeekChange": -0.7925054, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 0.9685, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.5, "recommendationMean": 1.77778, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 217322000, "totalCashPerShare": 3.055, "ebitda": -148184000, "totalDebt": 10794000, "quickRatio": 17.088, "currentRatio": 17.973, "debtToEquity": 4.249, "returnOnAssets": -0.3348, "returnOnEquity": -0.54269004, "freeCashflow": -78461248, "operatingCashflow": -130873000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 4.3529825, "regularMarketPrice": 0.9685, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634823000000, "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "postMarketChangePercent": 2.1683, "postMarketPrice": 0.9895, "postMarketChange": 0.021, "regularMarketChange": 0.04040003, "regularMarketDayRange": "0.86 - 0.9783", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1192961, "fiftyTwoWeekLowChange": 0.18550003, "fiftyTwoWeekLowChangePercent": 0.23690936, "fiftyTwoWeekRange": "0.783 - 5.66", "fiftyTwoWeekHighChange": -4.6914997, "fiftyTwoWeekHighChangePercent": -0.8288869, "fiftyTwoWeekChangePercent": -79.25054, "earningsTimestamp": 1740690301, "earningsTimestampStart": 1740690301, "earningsTimestampEnd": 1740690301, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.97, "epsForward": -2.15, "epsCurrentYear": -2.06286, "priceEpsCurrentYear": -0.4694938, "fiftyDayAverageChange": -0.45586002, "fiftyDayAverageChangePercent": -0.3200455, "twoHundredDayAverageChange": -1.0862149, "twoHundredDayAverageChangePercent": -0.52864504, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1744410522, "regularMarketTime": 1744401600, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]